Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resist...
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Abstract Background The mutational processes underlying non-coding cancer mutations and their biolog...
The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pat...
The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pat...
Breast cancer is one of the most common cancers and the second leading cause of cancer death in the ...
Acquired therapy resistance is a major problem for anticancer treatment, yet the underlying molecula...
Acquired therapy resistance is a major problem for anticancer treatment, yet the underlying molecula...
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Abstract Background The mutational processes underlying non-coding cancer mutations and their biolog...
The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pat...
The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pat...
Breast cancer is one of the most common cancers and the second leading cause of cancer death in the ...
Acquired therapy resistance is a major problem for anticancer treatment, yet the underlying molecula...
Acquired therapy resistance is a major problem for anticancer treatment, yet the underlying molecula...
Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer. Endocrin...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...